AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) EBITDA
AbbVie Inc.'s EBITDA for fiscal 2025 was $24.1B, up 9.37% from $22.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $25.6B. Over the past ten years it has ranged from $8.1B (fiscal 2018) to $26.6B (fiscal 2022); the current reading is higher than 73% of that period. AbbVie Inc. ranks 4th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $24.1B | 9.37% |
| FY2024 | $22.0B | (14.35%) |
| FY2023 | $25.7B | (3.39%) |
| FY2022 | $26.6B | 0.53% |
| FY2021 | $26.4B | 48.28% |
| FY2020 | $17.8B | 18.89% |
| FY2019 | $15.0B | 84.09% |
| FY2018 | $8.1B | (26.24%) |
| FY2017 | $11.0B | 4.91% |
| FY2016 | $10.5B | 25.75% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $8.3B | 40.31% |
| Mar 2026 | $5.9B | (9.26%) |
| Dec 2025 | $6.5B | 35.67% |
| Sep 2025 | $4.8B | (30.67%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| LLY Eli Lilly and Company compare | $35.7B |
| JNJ Johnson & Johnson compare | $34.9B |
| ABBV AbbVie Inc. | $25.6B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. compare | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. compare | $16.5B |
| MRK Merck & Co., Inc. compare | $13.7B |
| GILD Gilead Sciences, Inc. compare | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement